The U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim announced today.
Boston-Androgen deprivation therapy – one of the most common treatments for prostate cancer – may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and other institutions.
Cell Therapeutics, Inc. (CTI) announced preliminary results from a investigator-sponsored phase II study of XYOTAX(TM) (paclitaxel poliglumex) in patients with androgen independent prostate cancer, the majority of whom had failed prior treatment with taxane chemotherapy.
AstraZeneca announced the commencement of a new Phase III study of its new investigational once-daily orally administered drug, vandetanib (ZACTIMA(R), ZD6474).
French CNRS researchers with a group of scientists from Institut Curie and INSERM have used two-photon microscopy to demonstrate, for the first time in vivo and real-time, how T lymphocytes infiltrate a solid tumour in order to fight it. How is a tumour destroyed by T lymphocytes? This scenario has recently been visualised and published in the journal of Experimental Medicine.
Academics have found, for the first time, smells from healthy feces and people with infectious diarrhea differ significantly in their chemical composition and could be used to diagnose quickly diseases such as Clostridium difficile (C. Diff.).
Shire plc and its collaborative partner New River Pharmaceuticals Inc., announce the U.S. Food and Drug Administration has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of attention deficit hyperactivity disorder. VYVANSE is a prodrug that is therapeutically inactive until metabolized in the body.
GlaxoSmithKline today announced the start of an international Phase III trial of its investigational cancer treatment Tykerb? (lapatinib) in squamous cell carcinoma of the head and neck (SCCHN).
A controversial health centre where NHS patients will be treated by a private company has been opened.
Chronic kidney disease (CKD), a serious and progressive medical condition, has been and remains under-identified. While it is easy and inexpensive to test for kidney function, people who are at high risk for CKD are not routinely screened.